Skip to main content
Logo Logo Logo
  • Investors
    • For Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • AustriaDeutsch
    • BelgiumNederlands Français
    • BrazilPortuguês
    • CanadaFrançais English
    • DenmarkDansk
    • FranceFrançais
    • GermanyDeutsch
    • IrelandEnglish
    • ItalyItaliano
    • Japan日本語
    • LuxembourgFrançais Deutsch
    • NetherlandsNederlands
    • PortugalPortuguês
    • SpainEspañol
    • SwedenSvenska
    • SwitzerlandFrançais Deutsch Italiano
    • Taiwan繁體中文
    • United KingdomEnglish
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • AustriaDeutsch
    • BelgiumNederlands Français
    • BrazilPortuguês
    • CanadaFrançais English
    • DenmarkDansk
    • FranceFrançais
    • GermanyDeutsch
    • IrelandEnglish
    • ItalyItaliano
    • Japan日本語
    • LuxembourgFrançais Deutsch
    • NetherlandsNederlands
    • PortugalPortuguês
    • SpainEspañol
    • SwedenSvenska
    • SwitzerlandFrançais Deutsch Italiano
    • Taiwan繁體中文
    • United KingdomEnglish
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit

  • Investors

    Investors
    • For Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs

  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)

  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy

  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion

  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us

  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
Submitted by Anonymous (not verified) on Tue, 19 Aug 2025 - 00:56

Alnylam Announces Expansion of U.S. Manufacturing Facility

$250 million investment will add capacity and new enzymatic ligation capabilities

corporate-responsibility
Learn More ›
Our Science Green dna
14

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved